- LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system
- This system provides several advantages over technologies that are currently available for treating tumors with proton therapy
- The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers.
At a glance
- Company
- LIXTE Biotechnology Holdings
- Ticker
- NASDAQ: LIXT
- Announcement
- Acquisition
Products and programs
Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What did LIXTE acquire from Liora Technologies?
The release says LIXTE acquired Liora Technologies, which is becoming a wholly owned subsidiary. The deal also includes Liora’s proprietary LiGHT System, described as a proton therapy system for treating tumors. The release characterizes the system as offering advantages over other technologies currently available for tumor treatment, but does not specify those advantages in the provided text.
What is LB-100 designed to do?
The release identifies LB-100 as LIXTE’s lead clinical candidate and says it is designed to boost the activity of chemotherapy and immunotherapy. It also says LB-100 complements the LiGHT System. The provided text does not describe clinical results, a treatment regimen, or the specific way the candidate might work alongside proton therapy.
How does proton therapy treat tumors?
Proton therapy is a form of radiation treatment that directs beams of protons toward a tumor. Protons can deposit much of their energy at a controlled depth, which may help limit radiation exposure to some surrounding tissues compared with other radiation approaches. Whether it is appropriate depends on factors such as the tumor and the patient’s care plan.
